Survival After the Diagnosis of Mild‐to‐Moderate Alzheimer's Disease Dementia: A 15‐Year National Cohort Study in Taiwan
- 22 September 2024
- journal article
- research article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (9) , e6152
Abstract
Objectives: Pharmacological and non‐pharmacological interventions are mostly designed for patients with early Alzheimer's disease (AD) dementia. Long‐term case management and planning for the remainder of life with disability require an estimation of the survival duration.Methods: This cohort study utilized data from the National Health Insurance Research Database, Taiwan, to identify incident cases of mild‐to‐moderate AD dementia diagnosed from 2000 to 2002, followed through December 31, 2017. A multivariate Cox proportional hazards regression model was constructed to compare the independent effects of age, sex, and comorbidities on all‐cause mortality risk. Cumulative survival rates and survival times were estimated.Results: A total of 5258 incident cases were identified, all treated with cholinesterase inhibitors after diagnosis confirmation by an expert committee. During the 15‐year follow‐up period, 4331 deaths occurred. The 1‐, 3‐, 5‐, 10‐, and 15‐year cumulative survival rates were 95, 92, 67, 37, and 18, respectively. The median (95% CI) survival time after diagnosis was 7.69 (7.46–7.90) years overall, 6.37 (6.06–6.65) years in men, and 8.81 (8.49–9.12) years in women. After stratification by age and number of comorbidities, the median survival time ranged from 13.72 (ages 40–64) to 5.29 (ages ≥ 80) years among those without comorbidities. For those with ≥ 3 comorbidities, the median survival times decreased to 6.43 for individuals diagnosed at ages 40–64 and to 2.98 years for those diagnosed at age 80 or older.Conclusions: This nationwide, large, long‐term cohort study provided survival rates and durations from diagnosis to death, varying by sex, age group, and presence/number of comorbidities. This information can serve as a foundation for further cost‐effectiveness studies on new treatments, and may aid clinicians, patients, and families in shared decision‐making and advance personalized care planning for early dementia cases.Keywords
This publication has 21 references indexed in Scilit:
- Pharmacological and non‐pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic reviewJournal of Sleep Research, 2020
- Decomposing Urban and Rural Disparities of Preventable ED Visits Among Patients With Alzheimer's Disease and Related Dementias: Evidence of the Availability of Health Care ResourcesThe Journal of Rural Health, 2020
- Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: A meta-analysis of longitudinal studiesAgeing Research Reviews, 2019
- Mortality From Heart Failure and Dementia in the United States: CDC WONDER 1999–2016Journal of Cardiac Failure, 2019
- Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 PatientsInternational Journal of Neuropsychopharmacology, 2017
- Survival after dementia diagnosis in five racial/ethnic groupsAlzheimer's & Dementia, 2017
- Earlier Age of Dementia Onset and Shorter Survival Times in Dementia Patients With DiabetesAmerican Journal of Epidemiology, 2013
- Survival in dementia and predictors of mortality: a reviewInternational Journal of Geriatric Psychiatry, 2013
- Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementiaInternational Psychogeriatrics, 2012
- Survival Following a Diagnosis of Alzheimer DiseaseArchives of Neurology, 2002